



Request for Cure

Pursuant to 30 ILCS 500/50-57, the Chief Procurement Officer for General Services may, at the request of the State Purchasing Officer and agency head, permit a cure during an active procurement if a violation or deficiency of the Procurement Code, or of the procurement rules, regulations, policies, or practices promulgated by a chief procurement officer occurs.

Instructions for Submission: Complete sections 1-3. The State Purchasing Officer should provide the "Request for Cure" form to the Chief Procurement Officer with documentation as needed to support the request.

1. Procurement Deficiency

1.1 State Agency Name	DOT - Transportation
1.2 BidBuy Reference Number	25-494DOT-FINAD-B-46327
1.3 Procurement Description	IDOT Recruiting Hiring & Retention Efficiency Study - RFP
1.4 Date Agency notified SPO of the violation or deficiency	Apr 7, 2026
1.5 Provide a clear description of the violation or deficiency, including reference to the statute, rule, regulation, CPO Notice, or practice lacking compliance.	

In this procurement, a procedural deficiency has occurred related to the offer-hold period.

Under JCAR 1.2005(d)(2), offers may not be held for more than 180 days unless otherwise approved. The 180-day offer-hold period for this solicitation has expired before the procurement could be completed. As a result, the solicitation is no longer in compliance with the requirement in Section 1.2005(d)(2) of the Chief Procurement Officer's Administrative Rules.

This deficiency does not affect the fairness or competitiveness of the procurement but requires a permitted cure or waiver to allow the procurement to proceed. It is in the best interest of the State to waive the requirement in Section 1.2005(d)(2) and permit a cure so the solicitation may be completed.

2. Justification to Cure the Violation or Deficiency

Provide a detailed explanation why the benefits of permitting a cure outweigh the potential harm to stakeholders.

The potential harm of granting the extension is minimal. Vendors were already informed of the longer hold period and have not been asked to change their pricing or proposals. In contrast, denying the extension could result in the bid firm time expiring, forcing cancellation and re-procurement, which would cause greater delays, added costs, and loss of work already completed.

Most importantly, this procurement supports a critical study intended to position Illinois as a national leader in transportation and infrastructure while improving recruitment, hiring, and retention. Allowing sufficient time ensures the Agency can select the best-value consultant and achieve these long-term goals.

The Agency had previously reached out to the offerors to request they hold their pricing firm until May 2nd, 2026, and had received affirmative responses from each offeror.

For these reasons, the benefits of permitting the cure clearly outweigh any potential harm.

3. Recommended Action Necessary to Cure the Violation or Deficiency

Provide a clear description of the action necessary to cure the violation or deficiency, including the party(ies) that will undertake the action and the time frame to complete each action.



Request for Cure

Permitting a cure through an additional extension of the bid firm date will provide greater benefit than harm to all stakeholders. The Agency has taken reasonable and proactive steps to manage the procurement timeline, including obtaining CPO approval to extend the offer firm date, completing technical evaluations, holding four (4) oral presentations, and completing the evaluations of the presentations with no outliers being identified.

Accordingly, the Agency is requesting an additional extension of the bid firm date to May 2, 2026, to ensure adequate time to complete the remaining procurement activities in a thorough and compliant manner. Granting this cure will provide the Agency sufficient time to conduct price opening and negotiations. The remaining 24 days will be adequate to complete all remaining steps through price opening and the Best and Final Offer (BAFO) process. This need is driven in part by a vendor protest received on February 23, 2026, and the subsequent CPO determination issued on April 3, 2026, which impacted the overall procurement timeline.

Approval of this extension will allow the Agency to proceed with price opening in the next couple of days and complete the procurement award process without disruption.

4. Agency Head and State Purchasing Officer Attestation

The agency head (designee not permitted) and State Purchasing Officer (SPO) individually attest: "I believe the integrity, transparency, and efficiency of the procurement can be maintained while permitting the cure."

Agency Head Name	Gia Biagi	Date	04/09/26 9:20 AM CDT
Agency Head Signature	Signed by:  03690F3666F64C9...		
SPO Name	Adam Aldridge	Date	Apr 8, 2026
SPO Signature	Adam David Aldridge Digitally signed by Adam David Aldridge Date: 2026.04.08 08:35:04 -05'00'		

5. Required Action to Cure or Rationale for Denying the Cure Request

The offer firm time is extended to May 2, 2026.

6. Chief Procurement Officer for General Services Determination

6.1 ☒ I authorize curing the violation or deficiency when following the action in section 5.

6.2 ☐ I deny the request to cure the violation or deficiency in subsection 1.4 based on the rationale in section 5.

Ellen H. Daley Signature		Date	April 16, 2026
--------------------------	---	------	----------------